These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 27715904)
21. Utilization of buprenorphine and methadone among opioid users who inject drugs. Tsui JI; Burt R; Thiede H; Glick SN Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591 [TBL] [Abstract][Full Text] [Related]
22. Challenges to implementing opioid substitution therapy in Ukrainian prisons: Personnel attitudes toward addiction, treatment, and people with HIV/AIDS. Polonsky M; Azbel L; Wickersham JA; Taxman FS; Grishaev E; Dvoryak S; Altice FL Drug Alcohol Depend; 2015 Mar; 148():47-55. PubMed ID: 25620732 [TBL] [Abstract][Full Text] [Related]
23. Impact of opioid maintenance therapy in the community on re-incarceration in individuals with opioid use disorder-A linked cohort study. Paola R; Pavel S; Tatiana D; Hagit BN; Joseph M; Ronny B; Barak S J Subst Use Addict Treat; 2024 Aug; 163():209393. PubMed ID: 38754555 [TBL] [Abstract][Full Text] [Related]
24. Hepatitis C virus infection and pain sensitivity in patients on methadone or buprenorphine maintenance therapy for opioid use disorders. Tsui JI; Lira MC; Cheng DM; Winter MR; Alford DP; Liebschutz JM; Mao J; Edwards RR; Samet JH Drug Alcohol Depend; 2015 Aug; 153():286-92. PubMed ID: 26048638 [TBL] [Abstract][Full Text] [Related]
25. Exploring nonprescribed use of buprenorphine in the criminal justice system through qualitative interviews among individuals recently released from incarceration. Monico LB; Gryczynski J; Lee JD; Dusek K; McDonald R; Malone M; Sharma A; Cheng A; DeVeaugh-Geiss A; Chilcoat H J Subst Abuse Treat; 2021 Apr; 123():108267. PubMed ID: 33612198 [TBL] [Abstract][Full Text] [Related]
26. Buprenorphine maintenance treatment retention improves nationally recommended preventive primary care screenings when integrated into urban federally qualified health centers. Haddad MS; Zelenev A; Altice FL J Urban Health; 2015 Feb; 92(1):193-213. PubMed ID: 25550126 [TBL] [Abstract][Full Text] [Related]
27. Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap. Krawczyk N; Buresh M; Gordon MS; Blue TR; Fingerhood MI; Agus D J Subst Abuse Treat; 2019 Aug; 103():1-8. PubMed ID: 31229187 [TBL] [Abstract][Full Text] [Related]
28. The impact of buprenorphine/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients. Edelman EJ; Chantarat T; Caffrey S; Chaudhry A; O'Connor PG; Weiss L; Fiellin DA; Fiellin LE Drug Alcohol Depend; 2014 Jun; 139():79-85. PubMed ID: 24726429 [TBL] [Abstract][Full Text] [Related]
29. A trial of integrated buprenorphine/naloxone and HIV clinical care. Sullivan LE; Barry D; Moore BA; Chawarski MC; Tetrault JM; Pantalon MV; O'Connor PG; Schottenfeld RS; Fiellin DA Clin Infect Dis; 2006 Dec; 43 Suppl 4():S184-90. PubMed ID: 17109305 [TBL] [Abstract][Full Text] [Related]
30. "I Kicked the Hard Way. I Got Incarcerated." Withdrawal from Methadone During Incarceration and Subsequent Aversion to Medication Assisted Treatments. Maradiaga JA; Nahvi S; Cunningham CO; Sanchez J; Fox AD J Subst Abuse Treat; 2016 Mar; 62():49-54. PubMed ID: 26747509 [TBL] [Abstract][Full Text] [Related]
31. Attitudes toward opioid substitution therapy and pre-incarceration HIV transmission behaviors among HIV-infected prisoners in Malaysia: implications for secondary prevention. Bachireddy C; Bazazi AR; Kavasery R; Govindasamy S; Kamarulzaman A; Altice FL Drug Alcohol Depend; 2011 Jul; 116(1-3):151-7. PubMed ID: 21232882 [TBL] [Abstract][Full Text] [Related]
32. Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder. Evans EA; Wilson D; Friedmann PD Drug Alcohol Depend; 2022 Feb; 231():109254. PubMed ID: 35063323 [TBL] [Abstract][Full Text] [Related]
33. Why It's Inappropriate Not to Treat Incarcerated Patients with Opioid Agonist Therapy. Wakeman SE AMA J Ethics; 2017 Sep; 19(9):922-930. PubMed ID: 28905733 [TBL] [Abstract][Full Text] [Related]
34. Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention. D'Onofrio G; Chawarski MC; O'Connor PG; Pantalon MV; Busch SH; Owens PH; Hawk K; Bernstein SL; Fiellin DA J Gen Intern Med; 2017 Jun; 32(6):660-666. PubMed ID: 28194688 [TBL] [Abstract][Full Text] [Related]
35. Drug test results as a predictor of retention among patients using buprenorphine in a comprehensive outpatient treatment program. Campbell MD; Kolodner G; Spencer RA; DuPont RL J Addict Dis; 2016; 35(4):315-324. PubMed ID: 26757093 [TBL] [Abstract][Full Text] [Related]
37. Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial. Rich JD; McKenzie M; Larney S; Wong JB; Tran L; Clarke J; Noska A; Reddy M; Zaller N Lancet; 2015 Jul; 386(9991):350-9. PubMed ID: 26028120 [TBL] [Abstract][Full Text] [Related]
38. Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants. Fox AD; Chamberlain A; Sohler NL; Frost T; Cunningham CO J Subst Abuse Treat; 2015 Jan; 48(1):112-6. PubMed ID: 25205666 [TBL] [Abstract][Full Text] [Related]
39. Treating Opioid Use Disorder and Related Infectious Diseases in the Criminal Justice System. Winetsky D; Fox A; Nijhawan A; Rich JD Infect Dis Clin North Am; 2020 Sep; 34(3):585-603. PubMed ID: 32782103 [TBL] [Abstract][Full Text] [Related]
40. A retrospective analysis of treatment and retention outcomes of pregnant and/or parenting women with opioid use disorder. Lopian KM; Chebolu E; Kulak JA; Kahn LS; Blondell RD J Subst Abuse Treat; 2019 Feb; 97():1-6. PubMed ID: 30577894 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]